
Opinion|Videos|July 28, 2026
When Primary OSA Therapy Isn't Enough: Counseling on Residual Sleepiness
Winter opens the discussion by highlighting that millions of Americans with narcolepsy and OSA suffer from undertreated EDS. He sets the stage for understanding the unmet need that solriamfetol addresses.
Advertisement
Episodes in this series
Megan Maroney, PharmD, BCPP, addresses patients who remain sleepy despite adherence to primary OSA therapies like CPAP, noting that these devices may resolve airway obstruction without fully treating residual EDS. She discusses the point at which lingering sleepiness should prompt a conversation about adding pharmacologic treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
2
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
3
What Real-World Data Show About Moving Patients From Humira to Biosimilars
4
New Review Offers Framework for Sequencing Disease-Modifying Therapies in MS
5












































































































